Adamsbrown Wealth Consultants’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$466K Buy
3,627
+12
+0.3% +$1.41K 0.09% 88
2026
Q1
$435K Buy
3,615
+117
+3% +$13.5K 0.11% 78
2025
Q4
$368K Buy
3,498
+23
+0.7% +$2.16K 0.1% 85
2025
Q3
$292K Buy
3,475
+80
+2% +$6.59K 0.08% 93
2025
Q2
$269K Buy
3,395
+309
+10% +$24.6K 0.08% 86
2025
Q1
$277K Buy
3,086
+52
+2% +$4.86K 0.09% 77
2024
Q4
$302K Sell
3,034
-16
-0.5% -$1.65K 0.1% 73
2024
Q3
$346K Buy
3,050
+28
+0.9% +$3.33K 0.12% 59
2024
Q2
$374K Buy
3,022
+2
+0.1% +$258 0.15% 54
2024
Q1
$398K Sell
3,020
-87
-3% -$10.7K 0.16% 47
2023
Q4
$339K Sell
3,107
-4
-0.1% -$415 0.15% 54
2023
Q3
$320K Buy
3,111
+92
+3% +$9.92K 0.16% 52
2023
Q2
$348K Buy
3,019
+2
+0.1% +$227 0.18% 49
2023
Q1
$321K Buy
3,017
+3
+0.1% +$324 0.19% 49
2022
Q4
$334K Buy
3,014
+3
+0.1% +$307 0.2% 55
2022
Q3
$259K Buy
3,011
+3
+0.1% +$268 0.2% 66
2022
Q2
$274K Buy
3,008
+3
+0.1% +$266 0.22% 65
2022
Q1
$247K Buy
3,005
+92
+3% +$7.25K 0.2% 73
2021
Q4
$223K Buy
+2,913
New +$232K 0.2% 74

Other funds holding MRK

Adamsbrown Wealth Consultants's MRK Position: Q2 2026 in Review

Adamsbrown Wealth Consultants increased its Merck (MRK) stake by 0.33% in Q2 2026, buying an estimated $1.41K and bringing the position to 3,627 shares worth $466K. The position accounts for 0.09% of the portfolio, ranked #88.

Adamsbrown Wealth Consultants first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. 2,157 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Adamsbrown Wealth Consultants held 3,627 shares of Merck worth $466K as of Q2 2026.
  • Adamsbrown Wealth Consultants bought 12 Merck shares in Q2 2026, an estimated $1.41K.
  • Merck made up 0.09% of Adamsbrown Wealth Consultants's portfolio in Q2 2026, its #88 holding.
  • Adamsbrown Wealth Consultants first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
  • 2,157 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Adamsbrown Wealth Consultants's 13F filing for Q2 2026, filed 9 Jul 2026.